Skip to main content
PMC home page
Cytotechnology logoLink to Cytotechnology
. 2000 Oct;34(1-2):17–26. doi: 10.1023/A:1008138230896

Production of podophyllotoxin from Podophyllum hexandrum: a potential natural product for clinically useful anticancer drugs

Archana Giri 1, M Lakshmi Narasu 2,✉
PMCID: PMC3449733  PMID: 19003377

Abstract

Podophyllum hexandrum Royle of family Berberidaceae is an endangered medicinal plant. Rhizome ofP.hexandrum contains several lignans which posses antitumor activity. Podphyllotoxin is the most active cytotoxic natural product. It is used as starting compound for the synthesis of anticancer drug etoposide and teniposide. Podophyllotoxin acts as an inhibitor of microtubule assembly. These drugs are used for lung cancer, testicular cancer, neuroblastoma, hepatoma and other tumors. Besides this, it also shows antiviral activities by interfering with some critical viral processes. Availabilityof podophyllotoxin from plants has its limitations because of its intense collection from nature and lack of organized cultivation. The chemical synthesis of podophyllotoxin is considered to be very complicated as yet. The use of biotechnological approaches for the production of podophyllotoxin using cell cultures, organ cultures, and biotransformation route or by manipulating biosynthetic pathway proves to be an attractive alternative for production of podophyllotoxin. The present paper discusses the current status of research, limitations and future prospects for theproduction of podophyllotoxinin vitro.

Keywords: etoposide, metabolic engineering, Podophyllotoxin, Podophyllum hexandrum, teniposide, tissue culture

Full Text

The Full Text of this article is available as a PDF (114.0 KB).

References

  1. Aapro MS. Oral etopoide and pallitative treatment for small cell lung cancer [Commentary] Lancet. 1996;348:559. doi: 10.1016/S0140-6736(05)64791-5. [DOI] [PubMed] [Google Scholar]
  2. Arumugam N, Bhojwani SS. Somatic embryogenesis in tissue cultures ofPodophyllum hexandrum. Can J Bot. 1990;68:487–491. [Google Scholar]
  3. Baker JT, Borris RP, Carte B, et al. Natural product drug discovery and development: New perspectives on international collaboration. J Nat Prod. 1995;58:1325–1327. doi: 10.1021/np50123a003. [DOI] [PubMed] [Google Scholar]
  4. Berlin J, Bedorf N, Mollenschott C, Wray V, Sasse F, Hofle G. On the podophyllotoxins of root cultures ofLinum flavum. Planta Med. 1988;54:204–206. doi: 10.1055/s-2006-962404. [DOI] [PubMed] [Google Scholar]
  5. Cai X, Woo MH, Edick MJ, Relling MV. Simultaneous quantification of etoposide and its catechol metabolite in human plasma using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Sci Appl. 1999;728:241–250. doi: 10.1016/s0378-4347(99)00110-3. [DOI] [PubMed] [Google Scholar]
  6. Clark PI, Slevin ML. The clinical pharmacology of etoposide and teniposide. Clin Pharmacokin. 1987;12:223–252. doi: 10.2165/00003088-198712040-00001. [DOI] [PubMed] [Google Scholar]
  7. Chabner BA, Allegra CJ, Curt GA, et al. et al. Antineoplastic agents. In: Hardman JG, Limbird LE, Molinoff PB, et al.et al., editors. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed. New York: Mc Graw-Hill; 1996. pp. 1233–1287. [Google Scholar]
  8. Chabner BA, Myers CE. Clinical pharmacology of cancer chemotherapy. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. 3rd ed. Philadelphia: JB Lippincott Co; 1989. [Google Scholar]
  9. Chang LW, Yang CM, Chen CF, Deng JF. Experimental podophyllotoxin (bajiaolian) poisoning: I. Effects on the nervous system. Biomed Environ Sci. 1992;5:283–292. [PubMed] [Google Scholar]
  10. Charlton JL. Antiviral activity of lignans. J Nat Prod. 1998;61:1447–1451. doi: 10.1021/np980136z. [DOI] [PubMed] [Google Scholar]
  11. Cragg GM, Newman DJ, Snader KM. Natural products in drug discovery and development. J Nat Prod. 1997;60:52–60. doi: 10.1021/np9604893. [DOI] [PubMed] [Google Scholar]
  12. Damayanthi Y, Lown JW. Podophyllotoxins: Current status and recent developments. Curr Med Chem. 1998;5:205–252. [PubMed] [Google Scholar]
  13. Dewick PM. Tumour inhibitors from plants. In: Rahman AU, editor. Studies in Natural Products Chemistry, Vol 5. Amsterdam: Elsevier; 1989. pp. 459–503. [Google Scholar]
  14. Dorr RT, Von H. Cancer Chemotherapy Handbook. 2nd ed. Norwalk: Appleton and Lange; 1994. pp. 459–472. [Google Scholar]
  15. Drew SE, Conway SJ, Jenning P, Helliwell K. Determination of the aryltetralin lignan content of podophyllum resins and roots/rhizomes. J Pharm Pharmacol. 1987;39:738–739. doi: 10.1111/j.2042-7158.1987.tb06981.x. [DOI] [PubMed] [Google Scholar]
  16. Fay DA, Ziegler HW. Botanical sources differentiation ofPodophyllum resin by high performance liquid chromatography. J Liq Chromatogr. 1985;8:1501–1506. [Google Scholar]
  17. Ferguson LR, Pearson A. Chromosomal changes in Chinese hamster AAB cells caused by podophyllin, a common treatment for genital warts. Mutat Res. 1992;266:231–239. doi: 10.1016/0027-5107(92)90191-4. [DOI] [PubMed] [Google Scholar]
  18. Filly CM, Grah-Radford NR, Lacy JR, Heitner MA, Earnest MP. Neurologic manifestations of podophyllin toxicity. Neurology. 1982;32:308–311. doi: 10.1212/wnl.32.3.308. [DOI] [PubMed] [Google Scholar]
  19. Forsey SP, Rajapaksa D, Taylor NJ, Rodrigo R. Comprehensive synthetic route to eight diastereomericPodophyllum lignans. J Org Chem. 1989;54:4280–4290. [Google Scholar]
  20. Franssen MCR, Walton MJ. Biotransformations. In: Walton MJ, Brown DE, editors. Chemicals from Plants, Perspectives on Plant Secondary Products. London: Imperial College Press; 1999. pp. 277–325. [Google Scholar]
  21. Giri A and Lakhmi Narasu M (1999) Transgenic hairy roots: Recent trends and applications. Biotechnology Advances (in press). [DOI] [PubMed]
  22. Goel HC, Prasad J, Sharma A, Singh B. Antitumour and radioprotective action ofPodophyllum hexandrum. Indian J Exp Biol. 1998;36:583–587. [PubMed] [Google Scholar]
  23. Gowdey G, Lee RK, Carpenter WM. Treatment of HIVrelated hairy leukoplakia with podophyllum resin 25% solution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995;79:64–67. doi: 10.1016/s1079-2104(05)80076-9. [DOI] [PubMed] [Google Scholar]
  24. Greenwald RB, Conover CD, Pendri A, et al. Drug delivery of anticancer agents: Water soluble 4-poly ethylene glycol derivatives of the lignan, podophyllotoxin. J Controlled Release. 1999;61:281–294. doi: 10.1016/s0168-3659(99)00153-4. [DOI] [PubMed] [Google Scholar]
  25. Gupta R, Sethi KL. Conservation of medicinal plant resources. In: Jain SK, Mehra KL, editors. Conservation of tropical plant resources. Howrah: Botanical Survey of India; 1983. pp. 101–107. [Google Scholar]
  26. Handa SS, Chawla AS, Maninder A. Hypoglycemic plants: a review. Fitotherapia. 1989;60:195. [Google Scholar]
  27. Haskell CM. Cancer treatment. 3rd ed. Philadelphia: WB Saunders Co; 1990. [Google Scholar]
  28. Heyenga AG, Lucas JA, Dewick PM. Production of tumour-inhibitory lignans in callus cultures ofPodophyllum hexandrum. Plant Cell Rep. 1990;9:101–116. doi: 10.1007/BF00232404. [DOI] [PubMed] [Google Scholar]
  29. Holthuis JJM. Etoposide and teniposide. Biosynthesis, metabolism and clinical pharmokinetics. Pharm Weekbl (Sci) 1988;10:101–116. doi: 10.1007/BF01959294. [DOI] [PubMed] [Google Scholar]
  30. Inamori Y, Kubo M, Tsujibo H, Ogawa M, Kozawa M, Fujita E. The biological activities of podophyllotoxin compounds. Chem Pharm Bull. 1986;34:3928–3932. doi: 10.1248/cpb.34.3928. [DOI] [PubMed] [Google Scholar]
  31. Jackson DE, Dewick PM. Aryltetralin lignans fromPodophyllum hexandrum andPodophyllum peltatum. Phytochemistry. 1984;23:1147–1152. [Google Scholar]
  32. Kadkade PG. Formation of podophyllotoxins byPodophyllum peltatum tissue cultures. Naturwissenschaften. 1981;68:481–482. doi: 10.1007/BF01047526. [DOI] [PubMed] [Google Scholar]
  33. Kadkade PG. Growth and podophyllotoxin production in callus tissues ofPodophyllum peltatum. Plant Sci Lett. 1982;25:107–115. [Google Scholar]
  34. Kamil WM, Dewick PM. Biosynthetic relationship of aryltetralin lactone lignans to dibenzylbutyrolactone lignans. Phytochemistry. 1986;25:2093–2102. [Google Scholar]
  35. Kao WF, Hung DZ, Tsai WJ, Lin KP, Deng JF. Podophyllotoxin intoxication: toxic effects of Bajiaolian in herbal therapeutics. Hum Exp Toxicol. 1992;11:480–487. doi: 10.1177/096032719201100607. [DOI] [PubMed] [Google Scholar]
  36. Kaplan IW. Condyloma acuminata. New Orl Med Surg J. 1942;94:388–395. [Google Scholar]
  37. Krogh CME. In: Compendium of pharmaceuticals and specialties. Krogh CME, editor. Ottawa: Canadian Pharmaceutical Association.; 1993. pp. 1307–1308. [Google Scholar]
  38. Kutchan TM. Alkaloid biosynthesis-The basis for metabolic engineering of medicinal plants. The Plant Cell. 1995;7:1059–1070. doi: 10.1105/tpc.7.7.1059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. MacRae WD, Towers GHN. Biological activities of lignans. Phytochemistry. 1984;23:1207–1220. [Google Scholar]
  40. Mayeaux EJ, Jr, Harper MB, Barksdale W, Pope JB. Noncervical human papillomavirus genital infections. Am Fam Physician. 1995;52:1137–46. [PubMed] [Google Scholar]
  41. Montaldo PG, Figoli F, Zanette MI, et al. Pharmacokinetics of intrapleural versus intravenous etoposide (VP-16) and teniposide (VM-26) in patient with malignant pleural effusion. Oncology. 1990;47:55–61. doi: 10.1159/000226785. [DOI] [PubMed] [Google Scholar]
  42. Oostdam A, Mol JNM, Vanderplas LHW. Establishment of hairy root cultures ofLinum flavum producing the lignan 5-methoxy podophyllotoxin. Plant Cell Reports. 1993;12:474–477. doi: 10.1007/BF00234715. [DOI] [PubMed] [Google Scholar]
  43. Purohit MC, Bahuguna R, Maithani UC, Purohit AN, Rawat MSM. Variation in podophylloresin and podophyllotoxin contents in different populations ofPodophyllum hexandrum. Current Science. 1999;77:1078–1080. [Google Scholar]
  44. Przepiorka D, van Besien K, Khouri I, et al. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999;10:527–532. doi: 10.1093/oxfordjournals.annonc.a010369. [DOI] [PubMed] [Google Scholar]
  45. Rassmann I, Thodtmann R, Mross M, et al. Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion. Invest New Drugs. 1999;16:319–324. doi: 10.1023/a:1006293830585. [DOI] [PubMed] [Google Scholar]
  46. Reiser M, Jostingg A, Draube A, et al. Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization. Bone Marrow Transplant. 1999;23:1223–1228. doi: 10.1038/sj.bmt.1701791. [DOI] [PubMed] [Google Scholar]
  47. Richter A, Strausfeld U, Knippers R. Effects of VM-26 (teniposide), a specific inhibitor of type Iitopoisomerase, on SV-40 DNA replicationin vivo. Nucleic Acid Res. 1987;15:3455–3468. doi: 10.1093/nar/15.8.3455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Robles SJ, Buehler PW, Negrusz A, Adami GR. Permanent cell cycle arrest in asynchronously proliferating normal human fibroblasts treated with doxorubicin or etoposide but not camptothecin. Biochem Pharmacol. 1999;58:675–685. doi: 10.1016/s0006-2952(99)00127-6. [DOI] [PubMed] [Google Scholar]
  49. Romanelli F. Podophyllin. Clinical Toxicology Review. 1996;18:1–5. [Google Scholar]
  50. Rowinsky EK, Donehower . Vinca alkaloids and epipodophyllotoxins. In: Perry MC, editor. The Chemotherapy Source Book. Baltimore: Williams and Wilkins; 1992. pp. 359–83. [Google Scholar]
  51. Rust RW, Roth RR. Seed production and seedling establishment in the Mayapple,Podophyllum peltatum L. Am Midl Natur. 1981;105:51–60. [Google Scholar]
  52. Santana VM, Schell MJ, Williams R, et al. Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumours. Bone Marrow Transplant. 1992;10:457–462. [PubMed] [Google Scholar]
  53. Schacter L. Etoposide phosphate: what, why, where, and how? Semin Oncol. 1996;23:1–7. [PubMed] [Google Scholar]
  54. Stahelin HF, von Wartburg A. From podophyllotoxin glucoside to etoposide. Prog Drug Res. 1989;33:169–266. doi: 10.1007/978-3-0348-9146-2_8. [DOI] [PubMed] [Google Scholar]
  55. Stahelin HF, von Wartburg A. From the chemical and biological route from podophyllotoxin glucoside to etoposide, ninth Cain memorial award lecture. Cancer Res. 1991;51:5–15. [PubMed] [Google Scholar]
  56. Subrahmanyam D, Renuka B, Kumar GS, Vandana V, Deevi DS. 9-Deoxopodophyllotoxin derivatives as anti-cancer agents. Bioorg Med Chem Lett. 1999;9:2131–2134. doi: 10.1016/s0960-894x(99)00347-9. [DOI] [PubMed] [Google Scholar]
  57. Thakur RS. Plant drugs: Emerging areas of modern drug research. In: Govil JN, Singh VK, Hashmi S, editors. Glimpses in Plant Research Vol. XI. New Delhi: Today and Tomorrow's Publishers; 1993. pp. 371–375. [Google Scholar]
  58. Truedsson L, Geborek P, Sturfelt G. Antiproliferative effects on human peripheral blood mononuclear cells and inhibition of in vitro immunoglobulin synthesis by podophyllotoxin (CPH86) and by semisynthetic lignan glycosides (CPH82) Clip Exp Rheumatol. 1993;11:179–82. [PubMed] [Google Scholar]
  59. Ushio Y, Kochi M, Kuratsu J, Itoyama Y, Marubayashi T. Preliminary observations for a new treatment in children with primary intracranial yolk sac tumour or embroynal carcinoma. Report of five cases. J Neurosurg. 1999;90:133–137. doi: 10.3171/jns.1999.90.1.0133. [DOI] [PubMed] [Google Scholar]
  60. Van Uden W, Pras N, Visser JF, Malingre TM. Detection and identification ofpodophyllotoxin produced by cell cultures derived fromPodophyllum hexandrum Royle. Plant Cell Reports. 1989;8:165–168. doi: 10.1007/BF00716832. [DOI] [PubMed] [Google Scholar]
  61. Van Uden W, Pras N, Malingre TM. On the improvement of the podophyllotoxin production by phenylpropanoid precursor feeding to cell cultures ofPodophyllum hexandrum Royle. Plant Cell Tiss Org Cult. 1990;23:217–224. [Google Scholar]
  62. Van Uden W, Woerdenbag HJ, Pras N. Cyclodextrins as a useful tool for bioconversions in plant cell biotechnology. Plant Cell Tiss Org Cult. 1994;38:103–113. [Google Scholar]
  63. Viana MB, Oliveira M, Silva CM, et al. Etoposide in the treatment of six children with langerhans cell histiocytosis (histiocytosis X) Med Pediatr Oncol. 1991;19:289–294. doi: 10.1002/mpo.2950190414. [DOI] [PubMed] [Google Scholar]
  64. Walter MH, Grima-Pettenati J, Grand C, Boudet AM, Lamb CJ. Cinnamyl-alcohol dehydrogenase, a molecular marker specific for lignin synthesis: cDNA cloning and MRNA induction by fungal elicitor. Proc Natl Acad Sci USA. 1988;85:5546–5550. doi: 10.1073/pnas.85.15.5546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, Opaneye A, Temple C. Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomized study. Genitourin Med. 1997;73:184–187. doi: 10.1136/sti.73.3.184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Winik NJ, McKenna RW, Shuster JJ, et al. Secondary acute myeloid leukemia in children with lymphoblstic leukemia treated with etoposide. J Clin Oncol. 1993;11:209–217. doi: 10.1200/JCO.1993.11.2.209. [DOI] [PubMed] [Google Scholar]
  67. Woerdenbag HJ, Van Uden W, Frijlink HW, Lerk CF, Pras N, Malingre TM. Increased podophyllotoxin production inPodophyllum hexandrum cell suspension cultures after feeding coniferyl alcohol as aβ-cyclodextrin complex. Plant Cell Reports. 1990;9:97–100. doi: 10.1007/BF00231558. [DOI] [PubMed] [Google Scholar]
  68. Zhu XK, Guan J, Tachibana Y, Bastow KF, et al. Antitumor agents. 194. Synthesis and biological evaluations of 4-beta-mono-, di-, and trisubstituted aniline-4'-O-demethylpodophyllotoxin and related compounds with improved pharmacological profiles. J Med Chem. 1999;42:2441–2446. doi: 10.1021/jm990055f. [DOI] [PubMed] [Google Scholar]

Articles from Cytotechnology are provided here courtesy of Springer Science+Business Media B.V.

RESOURCES